← back to search

Maurizio Fava

Massachusetts General Hospital · US
Area of research
Pharmacology · Experimental and Cognitive Psychology
Research interest
Research interests include Treatment of Major Depression, Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes, Tryptophan and brain disorders, and Mental Health Research Topics.
h-index
137
citations
88,911
works
1,221
NIH funding
$3.9M
primary concept
email

Recent publications

Comparative effectiveness research trial for antidepressant incomplete and non-responders with treatment resistant depression (ASCERTAIN-TRD) a randomized clinical trial
Molecular Psychiatry 2024cited by 44position: lastdoi
Efficacy and Safety of Esmethadone (REL-1017) in Patients With Major Depressive Disorder and Inadequate Response to Standard Antidepressants
The Journal of Clinical Psychiatry 2024cited by 15position: firstdoi
Using Drift Diffusion and RL Models to Disentangle Effects of Depression On Decision-Making vs. Learning in the Probabilistic Reward Task.
2024cited by 10position: contributordoi
Rationale and Design for the BLOCK-SAH Study (Pterygopalatine Fossa Block as an Opioid-Sparing Treatment for Acute Headache in Aneurysmal Subarachnoid Hemorrhage): A Phase II, Multicenter, Randomized, Double-Blinded, Placebo-Controlled Clinical Trial with a Sequential Parallel Comparison Design
Neurocritical Care 2024cited by 8position: middledoi
EEG measures of brain arousal in relation to symptom improvement in patients with major depressive disorder: Results from a randomized placebo-controlled clinical trial.
2024cited by 1position: contributordoi
The future of psychopharmacology: a critical appraisal of ongoing phase 2/3 trials, and of some current trends aiming to de‐risk trial programmes of novel agents
World Psychiatry 2023cited by 107position: middledoi
Esmethadone-HCl (REL-1017): a promising rapid antidepressant
European Archives of Psychiatry and Clinical Neuroscience 2023cited by 30position: firstdoi
Clinical response to EPA supplementation in patients with major depressive disorder is associated with higher plasma concentrations of pro-resolving lipid mediators
Neuropsychopharmacology 2023cited by 27position: middledoi
Individuals with depression exhibiting a pro-inflammatory phenotype receiving omega-3 polyunsaturated fatty acids experience improved motivation-related cognitive function: Preliminary results from a randomized controlled trial
Brain Behavior & Immunity - Health 2023cited by 12position: middledoi
Efficacy and Safety of AXS-05 (Dextromethorphan-Bupropion) in Patients With Major Depressive Disorder
The Journal of Clinical Psychiatry 2022cited by 122position: middledoi
International pooled patient-level meta-analysis of ketamine infusion for depression: In search of clinical moderators
Molecular Psychiatry 2022cited by 77position: middledoi
Omega-3 Fatty Acids for Major Depressive Disorder With High Inflammation
The Journal of Clinical Psychiatry 2022cited by 51position: middledoi
Pharmacological Comparative Characterization of REL-1017 (Esmethadone-HCl) and Other NMDAR Channel Blockers in Human Heterodimeric N-Methyl-D-Aspartate Receptors
Pharmaceuticals 2022cited by 29position: middledoi
Esmethadone (REL-1017) and Other Uncompetitive NMDAR Channel Blockers May Improve Mood Disorders via Modulation of Synaptic Kinase-Mediated Signaling
International Journal of Molecular Sciences 2022cited by 22position: middledoi
Vortioxetine Versus Placebo for Major Depressive Disorder
The Journal of Clinical Psychiatry 2021cited by 36position: middledoi
The effect of single administration of intravenous ketamine augmentation on suicidal ideation in treatment-resistant unipolar depression: Results from a randomized double-blind study
European Neuropsychopharmacology 2021cited by 33position: middledoi
Transitioning From In-Person to Remote Clinical Research on Depression and Traumatic Brain Injury During the COVID-19 Pandemic: Study Modifications and Preliminary Feasibility From a Randomized Controlled Pilot Study.
2021cited by 9position: contributordoi
Transitioning From In-Person to Remote Clinical Research on Depression and Traumatic Brain Injury During the COVID-19 Pandemic: Study Modifications and Preliminary Feasibility From a Randomized Controlled Pilot Study (Preprint)
2021cited by 0position: contributordoi
An electroencephalographic signature predicts antidepressant response in major depression
Nature Biotechnology 2020cited by 299position: middledoi
A clinical approach to treatment resistance in depressed patients: What to do when the usual treatments don’t work well enough?
The World Journal of Biological Psychiatry 2020cited by 86position: middledoi
Dose- and time-dependent increase in circulating anti-inflammatory and pro-resolving lipid mediators following eicosapentaenoic acid supplementation in patients with major depressive disorder and chronic inflammation
Prostaglandins Leukotrienes and Essential Fatty Acids 2020cited by 60position: middledoi
Double-Blind, Placebo-Controlled, Proof-Of-Concept Trial of a Kappa-Selective Opioid Receptor Antagonist Augmentation in Treatment-Resistant Depression
Annals of Clinical Psychiatry 2020cited by 19position: firstdoi
Anger attacks are associated with persistently elevated irritability in MDD: findings from the EMBARC study
Psychological Medicine 2020cited by 16position: middledoi
PET imaging of neurotransmission using direct parametric reconstruction.
2020cited by 4position: contributordoi
Brain regulation of emotional conflict predicts antidepressant treatment response for depression.
2019cited by 42position: contributordoi
Time to relapse after a single administration of intravenous ketamine augmentation in unipolar treatment-resistant depression
Journal of Affective Disorders 2019cited by 33position: middledoi
Efficacy and Tolerability of Adjunctive Intravenous Sodium Nitroprusside Treatment for Outpatients With Schizophrenia
JAMA Psychiatry 2019cited by 29position: middledoi
Elevated Amygdala Activity in Young Adults With Familial Risk for Depression: A Potential Marker of Low Resilience
Biological Psychiatry Cognitive Neuroscience and Neuroimaging 2019cited by 29position: middledoi
Increased amygdala-visual cortex connectivity in youth with persecutory ideation
Psychological Medicine 2019cited by 24position: middledoi
Vortioxetine for attention deficit hyperactivity disorder in adults: A randomized, double-blind, placebo-controlled, proof-of-concept study.
2019cited by 13position: contributordoi

Grants

No grants ingested yet.

Frequent collaborators

Madhukar H. Trivedi · Southwestern Medical Center15 papers (2012–2024)Dan V. Iosifescu · Psychiatric Medical Center12 papers (2012–2024)David Mischoulon · Lemuel Shattuck Hospital11 papers (2012–2023) · 11 papers (2015–2024) · 7 papers (2012–2021) · 7 papers (2019–2024)Cristina Cusin · Harvard University7 papers (2017–2024)Bettina B. Hoeppner · Brown University7 papers (2017–2021)Marlene P. Freeman · Harvard University7 papers (2017–2021)Mark Hyman Rapaport · University of Utah6 papers (2017–2023)Sanjay J. Mathew · Baylor College of Medicine6 papers (2018–2024)Manish K. Jha · Southwestern Medical Center6 papers (2017–2024)Stephen M. Stahl · University of California System5 papers (2017–2024)Charles DeBattista · Stanford University5 papers (2018–2024) · 5 papers (2018–2021)Pamela J. Schettler · Emory University5 papers (2015–2023)Boadie W. Dunlop · Emory University5 papers (2017–2023)Roy H. Perlis · University of Colorado Denver5 papers (2012–2019)Diego A. Pizzagalli · Boston Medical Center5 papers (2014–2020)Patrick J. McGrath · Columbia University4 papers (2016–2020)